SCHEMBL4383885

SCHEMBL4383885

CC(C)[C@]1(C(=O)O)Cc2ccccc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.43
POLB P06746 2/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
APEX1 P27695 1/20 0.35
CYP2D6 P10635 2/20 0.34
TSHR P16473 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
PKM P14618 1/20 0.34
NFKB1 P19838 1/20 0.34
THPO P40225 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456633 0.81 PPARA (0.50) PPARAALDH1A1KDM4EMAPT
SCHEMBL3520901 0.76 POLB (0.47) PPARAPOLBLMNAL3MBTL1TRPM8
SCHEMBL28860430 0.74 HTR2A (0.39) POLBLMNAL3MBTL1TRPM8CYP2D6
SCHEMBL24043403 0.73 CYP2D6 (0.38) LMNACYP2D6TSHRCYP2C19CYP1A2
Acetic Acid SCHEMBL28604975 0.72 LMNA (0.42) POLBLMNAL3MBTL1TRPM8ALDH1A1
SCHEMBL26656365 0.72 TRPM8 (0.37) POLBLMNAL3MBTL1TRPM8CYP2D6
SCHEMBL28860431 0.72 TRPM8 (0.37) POLBLMNAL3MBTL1TRPM8CYP2D6
SCHEMBL7420613 0.72 PPARA (0.44) PPARALMNACYP2D6TSHRCYP2C19
SCHEMBL3380544 0.72 PPARA (0.44) PPARALMNACYP2D6TSHRCYP2C19
Carbamic Acid SCHEMBL28034072 0.71 LMNA (0.41) POLBLMNAL3MBTL1TRPM8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders LIPA, APOB, LCAT PPARA 111/4885POLB 3124/4885LMNA 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.